F8 and hemophilia A: To further evaluate the pre-clinical capability of engineered FoxP3FVIII cells we transferred these cells in combination with B-cell-depleting anti-mCD20 antibodies in Hemophilia A mice which contained previously induced FVIII inhibitors.